Role of interleukins in obesity: Implications for metabolic disease

Trends in Endocrinology and Metabolism

Volumn 25, Issue 6, 2014, Pages 312-319

  Febbraio, Mark A ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Beta cell; Inflammasome; Interleukins; Nutrient overload

Indexed keywords

AMYLIN; CARDIOTROPHIN 1; CILIARY NEUROTROPHIC FACTOR; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 2; INTERLEUKIN 33; INTERLEUKIN 36ALPHA; INTERLEUKIN 36BETA; INTERLEUKIN 36GAMMA; INTERLEUKIN 36RA; INTERLEUKIN 37; INTERLEUKIN 38; INTERLEUKIN 4; INTERLEUKIN 6; LEUKEMIA INHIBITORY FACTOR; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; ONCOSTATIN M; STAT3 PROTEIN; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; INTERLEUKIN DERIVATIVE;

CELL MATURATION; CELL MIGRATION; CELL PROLIFERATION; CYTOKINE PRODUCTION; ENERGY BALANCE; GENE EXPRESSION; HOMEOSTASIS; HUMAN; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SKELETAL MUSCLE; ANIMAL; ENERGY METABOLISM; IMMUNOLOGY; INFLAMMATION; METABOLISM; PHYSIOLOGY;

ANIMALS; ENERGY METABOLISM; HUMANS; INFLAMMATION; INTERLEUKINS; METABOLIC DISEASES; OBESITY;

EID: 84901820722     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2014.02.004     Document Type: Review

References (99)

1. Shoelson S.E., et al. Inflammation and insulin resistance. J. Clin. Invest. 2006, 116:1793-1801.
2. Hecht A., Goldner M.G. Reappraisal of the hypoglycemic action of acetylsalicylate. Metabolism 1959, 8:418-428.
3. Reid J., et al. Aspirin and diabetes mellitus. Br. Med. J. 1957, 2:1071-1074.
4. Hotamisligil G.S., et al. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993, 259:87-91.
5. Uysal K.T., et al. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997, 389:610-614.
6. Karin M., et al. NF-kappaB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer 2002, 2:301-310.
7. Yuan M., et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001, 293:1673-1677.
8. Cai D., et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat. Med. 2005, 11:183-190.
9. Karin M. Mitogen-activated protein kinase cascades as regulators of stress responses. Ann. N. Y. Acad. Sci. 1998, 851:139-146.
10. Hirosumi J., et al. A central role for JNK in obesity and insulin resistance. Nature 2002, 420:333-336.
11. Sabio G., et al. A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. Science 2008, 322:1539-1543.
12. Gao Z., et al. Serine phosphorylation of insulin receptor substrate 1 by inhibitor kappa B kinase complex. J. Biol. Chem. 2002, 277:48115-48121.
13. Brocker C., et al. Evolutionary divergence and functions of the human interleukin (IL) gene family. Hum. Genomics 2010, 5:30-55.
14. Feve B., Bastard J.P. The role of interleukins in insulin resistance and type 2 diabetes mellitus. Nat. Rev. Endocrinol. 2009, 5:305-311.
15. Dinarello C.A. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011, 117:3720-3732.
16. March C.J., et al. Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs. Nature 1985, 315:641-647.
17. Auron P.E., et al. Nucleotide sequence of human monocyte interleukin 1 precursor cDNA. Proc. Natl. Acad. Sci. U.S.A. 1984, 81:7907-7911.
18. Chaparro R.J., et al. Nonobese diabetic mice express aspects of both type 1 and type 2 diabetes. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:12475-12480.
19. Hypponen E., et al. Obesity, increased linear growth, and risk of type 1 diabetes in children. Diabetes Care 2000, 23:1755-1760.
20. Donath M.Y., et al. Cytokines and beta-cell biology: from concept to clinical translation. Endocr. Rev. 2008, 29:334-350.
21. van Belle T.L., et al. Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol. Rev. 2011, 91:79-118.
22. Butler A.E., et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003, 52:102-110.
23. Mandrup-Poulsen T. The role of interleukin-1 in the pathogenesis of IDDM. Diabetologia 1996, 39:1005-1029.
24. Maedler K., et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J. Clin. Invest. 2002, 110:851-860.
25. Larsen C.M., et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 2007, 356:1517-1526.
26. Ridker P.M., et al. Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am. Heart J. 2011, 162:597-605.
27. Schroder K., Tschopp J. The inflammasomes. Cell 2010, 140:821-832.
28. Masters S.L., et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes. Nat. Immunol. 2010, 11:897-904.
29. Westwell-Roper C., et al. IL-1 blockade attenuates islet amyloid polypeptide-induced proinflammatory cytokine release and pancreatic islet graft dysfunction. J. Immunol. 2011, 187:2755-2765.
30. Coll R.C., O'Neill L.A. The cytokine release inhibitory drug CRID3 targets ASC oligomerisation in the NLRP3 and AIM2 inflammasomes. PLoS ONE 2011, 6:e29539.
31. Wen H., et al. A role for the NLRP3 inflammasome in metabolic diseases: did Warburg miss inflammation?. Nat. Immunol. 2012, 13:352-357.
32. Horng T., Hotamisligil G.S. Linking the inflammasome to obesity-related disease. Nat. Med. 2011, 17:164-165.
33. De Nardo D., Latz E. NLRP3 inflammasomes link inflammation and metabolic disease. Trends Immunol. 2011, 32:373-379.
34. Turner N., et al. Distinct patterns of tissue-specific lipid accumulation during the induction of insulin resistance in mice by high-fat feeding. Diabetologia 2013, 56:1638-1648.
35. Schmitz-Peiffer C., et al. Ceramide generation is sufficient to account for the inhibition of the insulin-stimulated PKB pathway in C2C12 skeletal muscle cells pretreated with palmitate. J. Biol. Chem. 1999, 274:24202-24210.
36. Verheij M., et al. Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature 1996, 380:75-79.
37. Holland W.L., et al. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab. 2007, 5:167-179.
38. Bruce C.R., et al. Overexpression of sphingosine kinase 1 prevents ceramide accumulation and ameliorates muscle insulin resistance in high-fat diet-fed mice. Diabetes 2012, 61:3148-3155.
39. Vandanmagsar B., et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat. Med. 2011, 17:179-188.
40. Stienstra R., et al. Inflammasome is a central player in the induction of obesity and insulin resistance. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:15324-15329.
41. Stienstra R., et al. The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metab. 2010, 12:593-605.
42. Alboni S., et al. Interleukin 18 in the CNS. J. Neuroinflammation 2010, 7:9.
43. Shapiro L., et al. Interleukin 18 stimulates HIV type 1 in monocytic cells. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:12550-12555.
44. Esposito K., et al. Weight loss reduces interleukin-18 levels in obese women. J. Clin. Endocrinol. Metab. 2002, 87:3864-3866.
45. Aso Y., et al. Relationships of plasma interleukin-18 concentrations to hyperhomocysteinemia and carotid intimal-media wall thickness in patients with type 2 diabetes. Diabetes Care 2003, 26:2622-2627.
46. Netea M.G., et al. Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance. Nat. Med. 2006, 12:650-656.
47. Zorrilla E.P., et al. Interleukin-18 controls energy homeostasis by suppressing appetite and feed efficiency. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:11097-11102.
48. Henao-Mejia J., et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012, 482:179-185.
49. Inoue H., et al. Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo. Nat. Med. 2004, 10:168-174.
50. Pedersen B.K., Febbraio M.A. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol. Rev. 2008, 88:1379-1406.
51. Lindegaard B., et al. Interleukin-18 activates skeletal muscle AMPK and reduces weight gain and insulin resistance in mice. Diabetes 2013, 62:3064-3074.
52. Miller A.M. Role of IL-33 in inflammation and disease. J. Inflamm. 2011, 8:22.
53. Wood I.S., et al. IL-33, a recently identified interleukin-1 gene family member, is expressed in human adipocytes. Biochem. Biophys. Res. Commun. 2009, 384:105-109.
54. Miller A.M., et al. Interleukin-33 induces protective effects in adipose tissue inflammation during obesity in mice. Circ. Res. 2010, 107:650-658.
55. Febbraio M.A. gp130 receptor ligands as potential therapeutic targets for obesity. J. Clin. Invest. 2007, 117:841-849.
56. Wellen K.E., Hotamisligil G.S. Inflammation, stress, and diabetes. J. Clin. Invest. 2005, 115:1111-1119.
57. Carey A.L., et al. Interleukin-6 and tumor necrosis factor-alpha are not increased in patients with Type 2 diabetes: evidence that plasma interleukin-6 is related to fat mass and not insulin responsiveness. Diabetologia 2004, 47:1029-1037.
58. Lagathu C., et al. Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. Biochem. Biophys. Res. Commun. 2003, 311:372-379.
59. Senn J.J., et al. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 2002, 51:3391-3399.
60. Kim H.J., et al. Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes 2004, 53:1060-1067.
61. Klover P.J., et al. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 2003, 52:2784-2789.
62. Pedersen B.K., Febbraio M.A. Point: interleukin-6 does have a beneficial role in insulin sensitivity and glucose homeostasis. J. Appl. Physiol. 2007, 102:814-816.
63. Mooney R.A. Counterpoint: interleukin-6 does not have a beneficial role in insulin sensitivity and glucose homeostasis. J. Appl. Physiol. 2007, 102:816-818. discussion 818-819.
64. Starkie R.L., et al. Carbohydrate ingestion attenuates the increase in plasma interleukin-6, but not skeletal muscle interleukin-6 mRNA, during exercise in humans. J. Physiol. 2001, 533:585-591.
65. Steensberg A., et al. Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6. J. Physiol. 2000, 529:237-242.
66. Hiscock N., et al. Skeletal myocytes are a source of interleukin-6 mRNA expression and protein release during contraction: evidence of fiber type specificity. FASEB J. 2004, 18:992-994.
67. Wojtaszewski J.F., et al. Insulin signaling and insulin sensitivity after exercise in human skeletal muscle. Diabetes 2000, 49:325-331.
68. Febbraio M.A., et al. Interleukin-6 is a novel factor mediating glucose homeostasis during skeletal muscle contraction. Diabetes 2004, 53:1643-1648.
69. van Hall G., et al. Interleukin-6 stimulates lipolysis and fat oxidation in humans. J. Clin. Endocrinol. Metab. 2003, 88:3005-3010.
70. Ellingsgaard H., et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat. Med. 2011, 17:1481-1489.
71. Shirazi R., et al. Glucagon-like peptide 1 receptor induced suppression of food intake, and body weight is mediated by central IL-1 and IL-6. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:16199-16204.
72. Pedersen B.K., Febbraio M.A. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat. Rev. Endocrinol. 2012, 8:457-465.
73. Wallenius V., et al. Interleukin-6-deficient mice develop mature-onset obesity. Nat. Med. 2002, 8:75-79.
74. Di Gregorio G.B., et al. Lipid and carbohydrate metabolism in mice with a targeted mutation in the IL-6 gene: absence of development of age-related obesity. Am. J. Physiol. Endocrinol. Metab. 2004, 287:E182-E187.
75. Matthews V.B., et al. Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance. Diabetologia 2010, 53:2431-2441.
76. Wunderlich F.T., et al. Interleukin-6 signaling in liver parenchymal cells suppresses hepatic inflammation and improves systemic insulin action. Cell Metab. 2010, 12:237-249.
77. Carey A.L., et al. Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes 2006, 55:2688-2697.
78. Al-Khalili L., et al. Signaling specificity of interleukin-6 action on glucose and lipid metabolism in skeletal muscle. Mol. Endocrinol. 2006, 20:3364-3375.
79. Watt M.J., et al. CNTF reverses obesity-induced insulin resistance by activating skeletal muscle AMPK. Nat. Med. 2006, 12:541-548.
80. Sadagurski M., et al. Human IL6 enhances leptin action in mice. Diabetologia 2010, 53:525-535.
81. Moore K.W., et al. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 2001, 19:683-765.
82. Joyce D.A., et al. Two inhibitors of pro-inflammatory cytokine release, interleukin-10 and interleukin-4, have contrasting effects on release of soluble p75 tumor necrosis factor receptor by cultured monocytes. Eur. J. Immunol. 1994, 24:2699-2705.
83. Cintra D.E., et al. Interleukin-10 is a protective factor against diet-induced insulin resistance in liver. J. Hepatol. 2008, 48:628-637.
84. Gao M., et al. Hydrodynamic delivery of mIL10 gene protects mice from high-fat diet-induced obesity and glucose intolerance. Mol. Ther. 2013, 21:1852-1861.
85. Kowalski G.M., et al. Deficiency of haematopoietic-cell-derived IL-10 does not exacerbate high-fat-diet-induced inflammation or insulin resistance in mice. Diabetologia 2011, 54:888-899.
86. Martinez F.O., et al. Alternative activation of macrophages: an immunologic functional perspective. Annu. Rev. Immunol. 2009, 27:451-483.
87. Chawla A., et al. Macrophage-mediated inflammation in metabolic disease. Nat. Rev. Immunol. 2011, 11:738-749.
88. Kang K., et al. Adipocyte-derived Th2 cytokines and myeloid PPARdelta regulate macrophage polarization and insulin sensitivity. Cell Metab. 2008, 7:485-495.
89. Stanya K.J., et al. Direct control of hepatic glucose production by interleukin-13 in mice. J. Clin. Invest. 2013, 123:261-271.
90. Jiang L.Q., et al. Autocrine role of interleukin-13 on skeletal muscle glucose metabolism in type 2 diabetic patients involves microRNA let-7. Am. J. Physiol. Endocrinol. Metab. 2013, 305:E1359-E1366.
91. Steel J.C., et al. Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol. Sci. 2012, 33:35-41.
92. Grabstein K.H., et al. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 1994, 264:965-968.
93. Carbo N., et al. Interleukin-15 antagonizes muscle protein waste in tumour-bearing rats. Br. J. Cancer 2000, 83:526-531.
94. Rinnov A., et al. Endurance training enhances skeletal muscle interleukin-15 in human male subjects. Endocrine 2013, 45:271-278.
95. Carbo N., et al. Interleukin-15 mediates reciprocal regulation of adipose and muscle mass: a potential role in body weight control. Biochim. Biophys. Acta 2001, 1526:17-24.
96. Quinn L.S., et al. Oversecretion of interleukin-15 from skeletal muscle reduces adiposity. Am. J. Physiol. Endocrinol. Metab. 2009, 296:E191-E202.
97. Almendro V., et al. Effects of interleukin-15 on lipid oxidation: disposal of an oral [(14)C]-triolein load. Biochim. Biophys. Acta 2006, 1761:37-42.
98. Nielsen A.R., et al. Association between interleukin-15 and obesity: interleukin-15 as a potential regulator of fat mass. J. Clin. Endocrinol. Metab. 2008, 93:4486-4493.
99. Barra N.G., et al. Interleukin-15 treatment improves glucose homeostasis and insulin sensitivity in obese mice. Diabetes Obes. Metab. 2012, 14:190-193.